Identification the Cause of Cerebral Infarction in Patients With Cancer
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 135710
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects with acute ischemic stroke who presented within 7 days from symptom onset
- Subjects who had embolic infarction outside the perforator territory revealed by diffusion-weighted imaging
- Subjects with undetermined cause of stroke despite of initial evaluation including electrocardiogram and brain imaging upon admission
- Subjects who performed brain magnetic resonance image (MRI) and MR angiography (MRA), cardiac work-ups (12-lead electrocardiography, transthoracic and/or transesophageal echocardiography with injection of agitated saline (or agitated saline transcranial Doppler monitoring), and 24-hour Holter and/or telemonitoring)
- Subjects with informed consent
Exclusion Criteria:
- Subjects with single subcortical infarction
- Subjects with primary brain tumor
- Inability to perform comprehensive studies
- Refusal or withdrawal of the consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cancer-associated stroke
Cryptogenic embolic stroke with active cancer
|
|
Cryptogenic embolic stroke
Cryptogenic embolic stroke without active cancer
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of deep vein thrombosis and microembolic signal in cancer related stroke patients
Time Frame: Within one week after enrollment
|
Venous thromboembolism was investigated via Doppler sonography and/or computed tomography pulmonary angiography combined with venous phase CT angiography of the lower extremities.
Microembolic signal was detected via transcranial Doppler sonography on symptomatic cerebral circulation
|
Within one week after enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of intravascular thrombosis on infarct volume
Time Frame: Within one week after enrollment
|
Infarct volume was measured by diffusion-weighted MR imaging and apparent diffusion coefficient calculated from imaging data.
Univariate and multivariate linear regression was performed in ESUS patients with cancer (adjusted for age, sex, overt DIC).
|
Within one week after enrollment
|
|
Impact of intravascular thrombosis on survival
Time Frame: Till the event of death occurs in enrolled patients
|
Survival time (in years) was measured by subtracting admission date from the date the patient had expired.
Cox proportional hazard analysis was used to evaluate association between intravascular thrombosis and survival (adjusted for age, sex, NIHSS, presence of overt DIC, infarct volume, metastasis, and histologic type).
|
Till the event of death occurs in enrolled patients
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chin-Sang Chung, MD, PhD, Samsung Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2014-07-136
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.